12/3/2007

Genentech has applied for regulatory approval to market Avastin as a treatment for breast cancer. The move follows a successful clinical trial of Avastin, in which 722 breast cancer patients who took the drug with the chemotherapy agent paclitaxel had stable tumors for an average of 11 months, compared to six months in the control group. FDA advisers are scheduled to meet Wednesday to consider the company's request.

Full Story:
Bloomberg

Related Summaries